Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.62 |
| ▸ | DRD2 | P14416 | 11/20 | 0.62 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.40 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445332 | 1.00 | DRD4 (0.62) | DRD4DRD2CHIT1CHIAHTR2C | |
| SCHEMBL7453514 | 1.00 | DRD4 (0.62) | DRD4DRD2CHIT1CHIAHTR2C | |
| SCHEMBL7621086 | 0.84 | DRD4 (0.59) | DRD4DRD2CHIT1CHIAHTR2C | |
| SCHEMBL7445533 | 0.81 | DRD4 (0.63) | DRD4DRD2CHIT1CHIAHTR2C | |
| SCHEMBL7449107 | 0.76 | DRD4 (0.58) | DRD4DRD2CHIT1CHIAHTR2C | |
| SCHEMBL7455730 | 0.67 | DRD2 (0.54) | DRD4DRD2HTR2CLMNA | |
| SCHEMBL15468332 | 0.67 | DRD2 (0.53) | DRD4DRD2HTR2CLMNA | |
| SCHEMBL26250989 | 0.65 | DRD2 (0.51) | DRD4DRD2 | |
| SCHEMBL28475644 | 0.64 | SLC6A2 (0.47) | CHIT1CHIA | |
| SCHEMBL12747509 | 0.63 | DRD2 (0.49) | DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025956-A1 | 1-azatricyclic-4-benzylpiperazines | HODGETTS KEVIN (US) | 2002-02-28 | — | — | US | claimed |
| US-6294530-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-25 | — | — | US | claimed |
| US-20020193364-A1 | 1-azatricyclic-4-benzylpiperazines | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | US | disclosed |
| US-6403591-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020025956-A1 | 1-azatricyclic-4-benzylpiperazines | HODGETTS KEVIN (US) | 2002-02-28 | — | — | US | disclosed |
| US-6294530-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025956-A1 | 1-azatricyclic-4-benzylpiperazines | GABRA5, GABRA1, GABBR1 | DRD4 67/4885DRD2 40/4885CHIT1 4269/4885 |
| US-20020193364-A1 | 1-azatricyclic-4-benzylpiperazines | GABRA5, GABRA1, GABBR1 | DRD4 67/4885DRD2 40/4885CHIT1 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.